{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T12:08:44Z","timestamp":1785413324307,"version":"3.56.0"},"reference-count":118,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T00:00:00Z","timestamp":1785283200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Psoriasis is a chronic, autoimmune skin disease driven by persistent inflammation and immune dysfunction that severely impairs quality of life and is associated with serious comorbidities, including psoriatic arthritis, cardiovascular diseases (CVDs), and depression. Emerging epidemiological evidence suggests an association between psoriasis and an increased risk of certain malignancies, such as breast cancer (BC) and non-Hodgkin\u2019s lymphoma (NHL), although the strength and consistency of these associations vary across study designs, and the underlying thrombo-inflammatory mechanisms remain incompletely understood. Several therapeutic approaches, including topical therapies, conventional systemic drugs (e.g., methotrexate and cyclosporine), and biological agents have been investigated for their potential associations with malignancy risk. However, the available evidence is heterogeneous and influenced by disease severity, treatment duration, cumulative exposure, and patient-related confounding factors. While some epidemiological studies have reported associations between conventional therapies and selected skin or hematological malignancies, combined or sequential treatment regimens further complicate the interpretation of treatment-related cancer risk. Similarly, Janus kinase (JAK) inhibitors have been associated with higher reported rates of lymphoma and non-melanoma skin cancer than tumor necrosis factor \u03b1 inhibitors (TNFi-\u03b1) in some observational studies. Recent studies also highlight the clinical utility of inflammatory markers, specifically the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte (PLR) ratio, and systemic immune-inflammation index (SII), for monitoring systemic inflammation and treatment response, while certain therapies may additionally influence CVD risk. Despite these advances, substantial heterogeneity across observational studies, meta-analyses, and Mendelian randomization analyses preclude definitive conclusions regarding causality. Overall, this review synthesizes the current epidemiological and mechanistic evidence linking psoriasis, chronic inflammation, therapeutic interventions, cancer risk, and cardiovascular comorbidities, while highlighting the need for large prospective studies and standardized analytical approaches.<\/jats:p>","DOI":"10.3390\/ijms27156780","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T08:16:52Z","timestamp":1785313012000},"page":"6780","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Inflammatory Manifestations, Therapeutic Interventions, and Cancer Risk in Psoriasis: Current Epidemiological and Mechanistic Evidence"],"prefix":"10.3390","volume":"27","author":[{"given":"Aikaterini","family":"Lymperi","sequence":"first","affiliation":[{"name":"Hephaestus Laboratory, School of Chemistry, Faculty of Sciences, Democritus University of Thrace, Kavala University Campus, 65404 Kavala, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-0837-7825","authenticated-orcid":false,"given":"Evgenia","family":"Lamprianidou","sequence":"additional","affiliation":[{"name":"Hephaestus Laboratory, School of Chemistry, Faculty of Sciences, Democritus University of Thrace, Kavala University Campus, 65404 Kavala, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Adamantidi","sequence":"additional","affiliation":[{"name":"Hephaestus Laboratory, School of Chemistry, Faculty of Sciences, Democritus University of Thrace, Kavala University Campus, 65404 Kavala, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Chatzikamari","sequence":"additional","affiliation":[{"name":"Hematology Department, General Hospital of Kavala, St Sillas, 65500 Kavala, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolaos","family":"Loizidis","sequence":"additional","affiliation":[{"name":"Rheumatology Department, General Hospital of Kavala, St Sillas, 65500 Kavala, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vassiliki","family":"Dania","sequence":"additional","affiliation":[{"name":"First Department of Orthopedic Surgery, School of Medicine, National and Kapodistrian University of Athens, ATTIKON University General Hospital, 12462 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0837-9778","authenticated-orcid":false,"given":"Alexandros","family":"Tsoupras","sequence":"additional","affiliation":[{"name":"Hephaestus Laboratory, School of Chemistry, Faculty of Sciences, Democritus University of Thrace, Kavala University Campus, 65404 Kavala, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Wei, Q., Wang, Z., Liu, X., Liang, H., and Chen, L. (2023). Association between Gastric Cancer and 12 Autoimmune Diseases: A Mendelian Randomization Study. Genes, 14.","DOI":"10.3390\/genes14101844"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/s41598-024-51903-0","article-title":"Exploring Potential Causal Associations between Autoimmune Diseases and Colorectal Cancer Using Bidirectional Mendelian Randomization","volume":"14","author":"Chen","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1080\/0284186X.2019.1619936","article-title":"Autoimmune Disease in Patients with Diffuse Large B-Cell Lymphoma: Occurrence and Impact on Outcome","volume":"58","author":"Valachis","year":"2019","journal-title":"Acta Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jso.27017","article-title":"Prognostic Impact of Autoimmune Disease in Oral Cavity Squamous Cell Carcinoma","volume":"126","author":"Pillai","year":"2022","journal-title":"J. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e70262","DOI":"10.1002\/mco2.70262","article-title":"Autoimmune Diseases: Molecular Pathogenesis and Therapeutic Targets","volume":"6","author":"Song","year":"2025","journal-title":"MedComm"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Trovato, E., Dragotto, M., Capalbo, E., Cartocci, A., Rubegni, P., and Calabrese, L. (2024). Risk of Skin Cancer in Patients with Psoriasis: Single-Center Retrospective Study Comparing Anti-TNF\u03b1 and Phototherapy. J. Clin. Med., 13.","DOI":"10.3390\/jcm13092452"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Long, J., Yang, M., Pang, Y., Kang, H., Liang, S., and Wang, D. (2024). The Causal Relationship between Psoriasis and Cancers: A Two-Sample Mendelian Randomization Analysis. Front. Oncol., 14.","DOI":"10.3389\/fonc.2024.1366958"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Adil, S., Paracha, R.Z., Tariq, S., Nisar, M., Ijaz, S., Siddiqa, A., Hussain, Z., and Amir, A. (2021). A Computational Systems Analyses to Identify Biomarkers and Mechanistic Link in Psoriasis and Cutaneous Squamous Cell Carcinoma. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.662528"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"155750","DOI":"10.1016\/j.cyto.2021.155750","article-title":"Emerging Roles for IL-11 in Inflammatory Diseases","volume":"149","author":"Fung","year":"2022","journal-title":"Cytokine"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kim, S.Y., Yoo, D.M., Chung, J., and Choi, H.G. (2022). Thyroid Cancer and Psoriasis: A Nested Case\u2013Control Study. Diagnostics, 12.","DOI":"10.3390\/diagnostics12102297"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Gheuc\u0103-Solov\u0103stru, L., V\u00e2\u0163\u0103, D., Halip, A.I., Patra\u015fcu, A., Cozma, A., and Porumb-Andrese, E. (2021). Psoriasis\u2014A Cancer Risk Factor?. Appl. Sci., 11.","DOI":"10.3390\/app11188366"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Tang, L., Yang, X., Liang, Y., Xie, H., Dai, Z., and Zheng, G. (2018). Transcription Factor Retinoid-Related Orphan Receptor \u0393t: A Promising Target for the Treatment of Psoriasis. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01210"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.4103\/njcp.njcp_200_23","article-title":"Psoriatic Inflammation-Induced Atypically Located Venous Thromboembolism: A Case of Immuno-Thrombosis","volume":"26","year":"2023","journal-title":"Niger. J. Clin. Pract."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"102665","DOI":"10.1016\/j.rpth.2024.102665","article-title":"A Cell-Based Model to Study Mechanisms of Endothelial-Dependent Thrombin Generation in Response to Inflammation and Its Modulation by Hydroxychloroquine","volume":"9","author":"Arachchillage","year":"2025","journal-title":"Res. Pract. Thromb. Haemost."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1161\/ATVBAHA.117.309846","article-title":"Tissue Factor: An Essential Mediator of Hemostasis and Trigger of Thrombosis","volume":"38","author":"Grover","year":"2018","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.4103\/ijd.IJD_630_20","article-title":"Hemostatic and Coagulation Profile in Psoriasis: A Hospital-Based Case Control Study","volume":"67","author":"Mir","year":"2022","journal-title":"Indian J. Dermatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3608","DOI":"10.1093\/eurheartj\/ehx145","article-title":"Risk of Venous Thromboembolism in Patients with Psoriatic Arthritis, Psoriasis and Rheumatoid Arthritis: A General Population-Based Cohort Study","volume":"39","author":"Ogdie","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Brandum, E.P., J\u00f8rgensen, A.S., Rosenkilde, M.M., and Hjort\u00f8, G.M. (2021). Dendritic Cells and CCR7 Expression: An Important Factor for Autoimmune Diseases, Chronic Inflammation, and Cancer. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22158340"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"e14101","DOI":"10.1111\/ijcp.14101","article-title":"The Utility of Systemic-Immune Inflammation Index for Predicting the Disease Activation in Patients with Psoriasis","volume":"75","author":"Tanacan","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Wang, W.-M., Wu, C., Gao, Y.-M., Li, F., Yu, X.-L., and Jin, H.-Z. (2021). Neutrophil to Lymphocyte Ratio, Platelet to Lymphocyte Ratio, and Other Hematological Parameters in Psoriasis Patients. BMC Immunol., 22.","DOI":"10.1186\/s12865-021-00454-4"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Li, L., Yao, D., Lu, Y., Deng, J., Wei, J., Yan, Y., Deng, H., Han, L., and Lu, C. (2020). Metabonomics Study on Serum Characteristic Metabolites of Psoriasis Vulgaris Patients with Blood-Stasis Syndrome. Front. Pharmacol., 11.","DOI":"10.3389\/fphar.2020.558731"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1111\/tmi.14052","article-title":"Assessing Systemic Inflammatory Markers in Psoriasis: A Retrospective Study","volume":"29","author":"Solak","year":"2024","journal-title":"Trop. Med. Int. Health"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Nowowiejska, J., Baran, A., Hermanowicz, J.M., Sieklucka, B., Pawlak, D., and Flisiak, I. (2023). Evaluation of Plasma Concentrations of Galectins-1, 2 and 12 in Psoriasis and Their Clinical Implications. Biomolecules, 13.","DOI":"10.3390\/biom13101472"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Zhao, X., Li, J., and Li, X. (2024). Association between Systemic Immune-Inflammation Index and Psoriasis: A Population-Based Study. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1305701"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e37236","DOI":"10.1097\/MD.0000000000037236","article-title":"Association of Systemic Inflammation Index with Psoriasis Risk and Psoriasis Severity: A Retrospective Cohort Study of NHANES 2009 to 2014","volume":"103","author":"Guo","year":"2024","journal-title":"Medicine"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Ma, R., Cui, L., Cai, J., Yang, N., Wang, Y., Chen, Q., Chen, W., Peng, C., Qin, H., and Ding, Y. (2024). Association between Systemic Immune Inflammation Index, Systemic Inflammation Response Index and Adult Psoriasis: Evidence from NHANES. Front. Immunol., 15.","DOI":"10.3389\/fimmu.2024.1323174"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"477","DOI":"10.4103\/ijd.ijd_935_21","article-title":"Evaluation of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Chronic Plaque Psoriasis","volume":"67","author":"Mondal","year":"2022","journal-title":"Indian J. Dermatol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.abd.2020.02.008","article-title":"Evaluation of Monocyte to HDL Cholesterol Ratio and Other Inflammatory Markers in Patients with Psoriasis","volume":"95","author":"Sirin","year":"2020","journal-title":"An. Bras. Dermatol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3577","DOI":"10.1007\/s13555-026-01733-x","article-title":"The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa\u2014A Narrative Review","volume":"16","author":"Lewandowska","year":"2026","journal-title":"Dermatol. Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00403-024-02972-8","article-title":"Evaluation of the Inflammatory Parameters as Potential Biomarkers of Systemic Inflammation Extent and the Disease Severity in Psoriasis Patients","volume":"316","author":"Zhang","year":"2024","journal-title":"Arch. Dermatol. Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Tiuc\u0103, O.M., Morariu, S.H., Mariean, C.R., Tiuc\u0103, R.A., Nicolescu, A.C., and Cotoi, O.S. (2024). Impact of Blood-Count-Derived Inflammatory Markers in Psoriatic Disease Progression. Life, 14.","DOI":"10.3390\/life14010114"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kiluk, P., Baran, A., Kaminski, T.W., Maciaszek, M., and Flisiak, I. (2019). The Level of FGF 21 as a New Risk Factor for the Occurrence of Cardiometabolic Disorders amongst the Psoriatic Patients. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122206"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Conic, R.R., Damiani, G., Schrom, K.P., Ramser, A.E., Zheng, C., Xu, R., McCormick, T.S., and Cooper, K.D. (2020). Psoriasis and Psoriatic Arthritis Cardiovascular Disease Endotypes Identified by Red Blood Cell Distribution Width and Mean Platelet Volume. J. Clin. Med., 9.","DOI":"10.3390\/jcm9010186"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"102428","DOI":"10.1016\/j.plefa.2022.102428","article-title":"Statin Therapy Upregulates Arachidonic Acid Status via Enhanced Endogenous Synthesis in Patients with Plaque Psoriasis","volume":"180","author":"Garshick","year":"2022","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1161\/ATVBAHA.119.314008","article-title":"Activated Platelets Induce Endothelial Cell Inflammatory Response in Psoriasis via COX-1","volume":"40","author":"Garshick","year":"2020","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1093\/jnci\/djad187","article-title":"Autoimmune Disease and the Risk of Anal Cancer in the US Population Aged 66 Years and Over","volume":"116","author":"Song","year":"2024","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"103187","DOI":"10.1016\/j.jaut.2024.103187","article-title":"Autoimmune Diseases and Female-Specific Cancer Risk: A Systematic Review and Meta-Analysis","volume":"144","author":"Fischer","year":"2024","journal-title":"J. Autoimmun."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7952","DOI":"10.1038\/s41467-024-51824-6","article-title":"An Observational and Genetic Investigation into the Association between Psoriasis and Risk of Malignancy","volume":"15","author":"Li","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_39","unstructured":"(2025, January 16). Clinical Chemistry\u2014Edition 9\u2014By William J. Marshall, MA, PhD, MSc, MBBS, FRCP, FRCPath, FRCPEdin, FRSB, FRSC, M\u00e1rta Lapsley, MB BCh BAO, MD, FRCPath, Andrew Day, MA MSc MBBS FRCPath and Kate ShipmanElsevier Health Inspection Copies. Available online: http:\/\/educate.elsevier.com\/book\/details\/9780702079368."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Z\u00e1dori, N., Szak\u00f3, L., V\u00e1ncsa, S., V\u00f6rhendi, N., O\u0161tarija\u0161, E., Kiss, S., Frim, L., Hegyi, P., and Czimmer, J. (2021). Six Autoimmune Disorders Are Associated with Increased Incidence of Gastric Cancer: A Systematic Review and Meta-Analysis of Half a Million Patients. Front. Immunol., 12.","DOI":"10.3389\/fimmu.2021.750533"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jtho.2021.12.014","article-title":"The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification","volume":"17","author":"Sauter","year":"2022","journal-title":"J. Thorac. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1001\/jamadermatol.2019.3056","article-title":"Association of Psoriasis with the Risk of Developing or Dying of Cancer","volume":"155","author":"Trafford","year":"2019","journal-title":"JAMA Dermatol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sarabia, S., Ranjith, B., Koppikar, S., and Wijeratne, D.T. (2022). Efficacy and Safety of JAK Inhibitors in the Treatment of Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-Analysis. BMC Rheumatol., 6.","DOI":"10.1186\/s41927-022-00287-7"},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Sugimoto, E., Matsuda, H., Shibata, S., Mizuno, Y., Koyama, A., Li, L., Taira, H., Ito, Y., Awaji, K., and Yamashita, T. (2023). Impact of Pretreatment Systemic Inflammatory Markers on Treatment Persistence with Biologics and Conventional Systemic Therapy: A Retrospective Study of Patients with Psoriasis Vulgaris and Psoriatic Arthritis. J. Clin. Med., 12.","DOI":"10.3390\/jcm12083046"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1001\/jamadermatol.2020.1300","article-title":"Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases: A Systematic Review and Meta-Analysis","volume":"156","author":"Esse","year":"2020","journal-title":"JAMA Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Andersen, C.S.B., Kvist-Hansen, A., Siewertsen, M., Enevold, C., Hansen, P.R., Kaur-Knudsen, D., Zachariae, C., Nielsen, C.H., Loft, N., and Skov, L. (2023). Blood Cell Biomarkers of Inflammation and Cytokine Levels as Predictors of Response to Biologics in Patients with Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24076111"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"20690","DOI":"10.1038\/s41598-022-23518-w","article-title":"Risk of Malignancy in Patients with Psoriasis According to Treatment Modalities in Korea: A Nationwide Cohort Study","volume":"12","author":"Hong","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e15804","DOI":"10.1111\/dth.15804","article-title":"Risk of Malignancy in Patients with Psoriasis Receiving Systemic Medications: A Nested Case-Control Study","volume":"35","author":"Chou","year":"2022","journal-title":"Dermatol. Ther."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"e12956","DOI":"10.1111\/phpp.12956","article-title":"Does the Risk of Basal Cell Carcinoma Increase in Patients with Psoriasis under Treatment?","volume":"40","author":"Sevdem","year":"2024","journal-title":"Photodermatol. Photoimmunol. Photomed."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4274\/turkderm.galenos.2022.56313","article-title":"Phototherapy","volume":"56","author":"Akyol","year":"2022","journal-title":"Turkderm"},{"key":"ref_51","first-page":"adv00365","article-title":"Methotrexate Use for Patients with Psoriasis and Risk of Cutaneous Squamous Cell Carcinoma: A Nested Case-Control Study","volume":"101","author":"Giannopoulos","year":"2021","journal-title":"Acta Derm.-Venereol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Cai, S., Perng, W.-T., Huang, J.Y., Chiou, J.-Y., Dong, L., and Wei, J.C. (2020). Neoplasm Risk in Rheumatic Diseases Has No Correlation with Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs Usage\u2014A Population-Based Nested Case\u2013Control Study. Front. Med., 7.","DOI":"10.3389\/fmed.2020.00473"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1038\/s41416-023-02172-7","article-title":"Use of Methotrexate and Risk of Skin Cancer: A Nationwide Case\u2013Control Study","volume":"128","author":"Polesie","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/s41392-023-01468-7","article-title":"Evolving Cognition of the JAK-STAT Signaling Pathway: Autoimmune Disorders and Cancer","volume":"8","author":"Xue","year":"2023","journal-title":"Sig. Transduct. Target. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1136\/ard-2023-224049","article-title":"JAK Inhibitors and the Risk of Malignancy: A Meta-Analysis across Disease Indications","volume":"82","author":"Russell","year":"2023","journal-title":"Ann. Rheum. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"117932","DOI":"10.1016\/j.bmc.2024.117932","article-title":"Design of a Potent and Selective Dual JAK1\/TYK2 Inhibitor","volume":"114","author":"Mammoliti","year":"2024","journal-title":"Bioorg. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"108224","DOI":"10.1016\/j.compbiolchem.2024.108224","article-title":"The Multiple-Action Allosteric Inhibition of TYK2 by Deucravacitinib: Insights from Computational Simulations","volume":"113","author":"Bao","year":"2024","journal-title":"Comput. Biol. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lee, H.-J., and Kim, M. (2023). Challenges and Future Trends in the Treatment of Psoriasis. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241713313"},{"key":"ref_59","first-page":"1491","article-title":"Risk of Cancer, Tuberculosis and Serious Infections in Patients with Ankylosing Spondylitis, Psoriatic Arthritis and Psoriasis Treated with IL-17 and TNF-\u03b1 Inhibitors: A Nationwide Nested Case-Control Analysis","volume":"41","author":"Kim","year":"2023","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Tsai, C.-J., Lin, Y.-C., Chen, C.-Y., Hung, C.-H., and Lin, Y.-C. (2023). The Effects of Biologics on Hematologic Malignancy Development in Patients with Ankylosing Spondylitis, Psoriasis, or Psoriatic Arthritis: A National Cohort Study. Biomedicines, 11.","DOI":"10.3390\/biomedicines11092510"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"9224241","DOI":"10.1155\/2023\/9224241","article-title":"The Risk of Lymphoproliferative Disorders and Skin Cancers in Patients with Psoriasis and Inflammatory Bowel Disease Administered Biologics","volume":"2023","author":"Jung","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2023.03.035","article-title":"Malignancy Rates through 5 Years of Follow-up in Patients with Moderate-to-Severe Psoriasis Treated with Guselkumab: Pooled Results from the VOYAGE 1 and VOYAGE 2 Trials","volume":"89","author":"Blauvelt","year":"2023","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40257-020-00512-4","article-title":"Malignancy Rates in Brodalumab Clinical Studies for Psoriasis","volume":"21","author":"Gottlieb","year":"2020","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1007\/s13555-024-01162-8","article-title":"Brodalumab: 5-Year US Pharmacovigilance Report","volume":"14","author":"Lebwohl","year":"2024","journal-title":"Dermatol. Ther."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1007\/s13555-023-00966-4","article-title":"Integrated Safety Analysis on Skin Cancers among Patients with Psoriasis Receiving Ixekizumab in Clinical Trials","volume":"13","author":"Smith","year":"2023","journal-title":"Dermatol. Ther."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Albayrak, H. (2023). Neutrophil-to-Lymphocyte Ratio, Neutrophil-to-Monocyte Ratio, Platelet-to-Lymphocyte Ratio, and Systemic Immune-Inflammation Index in Psoriasis Patients: Response to Treatment with Biological Drugs. J. Clin. Med., 12.","DOI":"10.20944\/preprints202308.0347.v1"},{"key":"ref_67","first-page":"67","article-title":"Tofacitinib","volume":"56","year":"2022","journal-title":"Turkderm"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/rmdopen-2020-001374","article-title":"Points to Consider for the Treatment of Immune-Mediated Inflammatory Diseases with Janus Kinase Inhibitors: A Systematic Literature Research","volume":"6","author":"Kerschbaumer","year":"2020","journal-title":"RMD Open"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s00109-023-02406-4","article-title":"A Simple Tool for Evaluation of Inflammation in Psoriasis: Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratio as Markers in Psoriasis Patients and Related Murine Models of Psoriasis-like Skin Disease","volume":"102","author":"Kommoss","year":"2024","journal-title":"J. Mol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"202","DOI":"10.5114\/ada.2020.94838","article-title":"The Effect of Biological Agent Treatment on Neutrophil-to-Lymphocyte Ratio, Platelet-to-Lymphocyte Ratio, Mean Platelet Volume, and C-Reactive Protein in Psoriasis Patients","volume":"37","author":"An","year":"2020","journal-title":"Adv. Dermatol. Allergol."},{"key":"ref_71","first-page":"e13457","article-title":"Neutrophil\/Platelet to Lymphocyte Ratio in Monitoring of Response to TNF-\u03b1 Inhibitors in Psoriatic Patients","volume":"33","author":"Nasiri","year":"2020","journal-title":"Dermatol. Ther."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/bjd.16776","article-title":"Identifying Demographic, Social and Clinical Predictors of Biologic Therapy Effectiveness in Psoriasis: A Multicentre Longitudinal Cohort Study","volume":"180","author":"Warren","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jamadermatol.2024.2463","article-title":"Noninferiority of 16-Week vs 8-Week Guselkumab Dosing in Super Responders for Maintaining Control of Psoriasis: The GUIDE Randomized Clinical Trial","volume":"160","author":"Eyerich","year":"2024","journal-title":"JAMA Dermatol."},{"key":"ref_74","first-page":"452","article-title":"Decrease in Inflammation Markers with Ustekinumab Treatment in Moderate-Severe Psoriasis","volume":"14","author":"Memet","year":"2021","journal-title":"Pam. Med. J."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e14114","DOI":"10.1111\/ijcp.14114","article-title":"The Effect of Secukinumab Treatment on Inflammatory Parameters in Patients with Psoriasis: A Multicentre Restrospective Study","volume":"75","author":"An","year":"2021","journal-title":"Int. J. Clin. Pract."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.clinthera.2021.06.008","article-title":"Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-Mediated Diseases","volume":"43","author":"Setyawan","year":"2021","journal-title":"Clin. Ther."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1136\/annrheumdis-2019-216761","article-title":"Incidence of Venous and Arterial Thromboembolic Events Reported in the Tofacitinib Rheumatoid Arthritis, Psoriasis and Psoriatic Arthritis Development Programmes and from Real-World Data","volume":"79","author":"Mease","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.5551\/jat.64767","article-title":"Cardiovascular Adverse Events Associated with Tumor Necrosis Factor-Alpha Inhibitors: A Real-World Pharmacovigilance Analysis","volume":"31","author":"Ma","year":"2024","journal-title":"J. Atheroscler. Thromb."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Nguyen, T.T., Jensen, C.G., Khoury, L., Deleuran, B., Blom, E.S., Breinholt, T., Christensen, R., and Skov, L. (2021). Effectiveness of Mind\u2013Body Intervention for Inflammatory Conditions: Results from a 26-Week Randomized, Non-Blinded, Parallel-Group Trial. J. Clin. Med., 10.","DOI":"10.3390\/jcm10143107"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"e26405","DOI":"10.2196\/26405","article-title":"The Effects of Modified Intermittent Fasting in Psoriasis (MANGO): Protocol for a Two-Arm Pilot Randomized Controlled Open Cross-over Study","volume":"11","author":"Grine","year":"2022","journal-title":"JMIR Res. Protoc."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Meneguin, S., de Godoy, N.A., Pollo, C.F., Miot, H.A., and de Oliveira, C. (2020). Quality of Life of Patients Living with Psoriasis: A Qualitative Study. BMC Dermatol., 20.","DOI":"10.1186\/s12895-020-00116-9"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s13075-023-03085-9","article-title":"More than Skin-Deep: Visceral Fat Is Strongly Associated with Disease Activity, Function and Metabolic Indices in Psoriatic Disease","volume":"25","author":"Blake","year":"2023","journal-title":"Arthritis Res. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Morariu, S.-H., Cotoi, O.S., Tiuc\u0103, O.M., Baican, A., Gheuc\u0103-Solov\u0103stru, L., Decean, H., Brihan, I., Silaghi, K., Biro, V., and \u0218erban-Pescar, D. (2024). Blood-Count-Derived Inflammatory Markers as Predictors of Response to Biologics and Small-Molecule Inhibitors in Psoriasis: A Multicenter Study. J. Clin. Med., 13.","DOI":"10.3390\/jcm13143992"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4274\/haseki.galenos.2023.9050","article-title":"Effect of Biological Therapy on Systemic Inflammatory Markers Among Patients with Chronic Plaque Psoriasis","volume":"61","year":"2023","journal-title":"Med. Bull. Haseki"},{"key":"ref_85","first-page":"e138","article-title":"English Version of Japanese Guidance for the Use of Oral Janus Kinase Inhibitors (JAK1 and TYK2 Inhibitors) in the Treatments of Psoriasis","volume":"50","author":"Saeki","year":"2023","journal-title":"J. Dermatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/jdv.19520","article-title":"Are Interleukin 17 and Interleukin 23 Inhibitors Associated with Malignancies?\u2014Insights from an International Population-Based Study","volume":"38","author":"Kridin","year":"2024","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling Pathways and Targeted Therapies for Psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Sig. Transduct. Target. Ther."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12016-024-08991-7","article-title":"The Immunology of Psoriasis-Current Concepts in Pathogenesis","volume":"66","author":"Sieminska","year":"2024","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Man, A.-M., Or\u0103san, M.S., Hoteiuc, O.-A., Ol\u0103nescu-Vaida-Voevod, M.-C., and Mocan, T. (2023). Inflammation and Psoriasis: A Comprehensive Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242216095"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Wang, L., Liu, R., Tang, Y., Ma, Y., Wang, G., Ruan, Q., and Zheng, S.J. (2025). Advances in Psoriasis Research: Decoding Immune Circuits and Developing Novel Therapies. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202508.1767.v1"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1080\/14712598.2025.2471093","article-title":"Psoriasis and Cancer: The Role of Inflammation, Immunosuppression, and Cancer Treatment","volume":"25","author":"Bruni","year":"2025","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Giraulo, C., De Palma, G., Plaitano, P., Esposito, R., Morretta, E., Monti, M.C., M\u00fcller, C.E., Cicala, C., and Morello, S. (2026). Oncostatin M Upregulates CD73 via the MAPK Pathway in Keratinocytes to Promote an Adenosine-Dependent Anti-Inflammatory Response in Psoriasis. Front. Immunol., 17.","DOI":"10.3389\/fimmu.2026.1698290"},{"key":"ref_93","doi-asserted-by":"crossref","unstructured":"Kim, J., Moreno, A., and Krueger, J.G. (2022). The Imbalance between Type 17 T-Cells and Regulatory Immune Cell Subsets in Psoriasis Vulgaris. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.1005115"},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"Jang, D., Lee, A.-H., Shin, H.-Y., Song, H.-R., Park, J.-H., Kang, T.-B., Lee, S.-R., and Yang, S.-H. (2021). The Role of Tumor Necrosis Factor Alpha (TNF-\u03b1) in Autoimmune Disease and Current TNF-\u03b1 Inhibitors in Therapeutics. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22052719"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"28929","DOI":"10.1038\/s41598-025-13992-3","article-title":"Identification of STAT3 and BIRC5 as Anoikis-Related Biomarkers in Psoriasis","volume":"15","author":"Bai","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Liu, T., Li, S., Ying, S., Tang, S., Ding, Y., Li, Y., Qiao, J., and Fang, H. (2020). The IL-23\/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. Front. Immunol., 11.","DOI":"10.3389\/fimmu.2020.594735"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"e70073","DOI":"10.1111\/1440-1681.70073","article-title":"Overexpression of miR-718 in Keratinocytes Affects the Psoriatic Inflammation via Targeting STAT1: In Vitro and In Vivo Evidence","volume":"52","author":"Rani","year":"2025","journal-title":"Clin. Exp. Pharmacol. Physiol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Huang, B., Lang, X., and Li, X. (2022). The Role of IL-6\/JAK2\/STAT3 Signaling Pathway in Cancers. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.1023177"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Wen, Y., Zhu, Y., Zhang, C., Yang, X., Gao, Y., Li, M., Yang, H., Liu, T., and Tang, H. (2022). Chronic Inflammation, Cancer Development and Immunotherapy. Front. Pharmacol., 13.","DOI":"10.3389\/fphar.2022.1040163"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Dobric\u0103, E.-C., Cozma, M.-A., G\u0103man, M.-A., Voiculescu, V.-M., and G\u0103man, A.M. (2022). The Involvement of Oxidative Stress in Psoriasis: A Systematic Review. Antioxidants, 11.","DOI":"10.3390\/antiox11020282"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1080\/13510002.2019.1658377","article-title":"Salidroside Inhibits MAPK, NF-\u03baB, and STAT3 Pathways in Psoriasis-Associated Oxidative Stress via SIRT1 Activation","volume":"24","author":"Xu","year":"2019","journal-title":"Redox. Rep."},{"key":"ref_102","doi-asserted-by":"crossref","unstructured":"Ple\u0144kowska, J., Gabig-Cimi\u0144ska, M., and Mozolewski, P. (2020). Oxidative Stress as an Important Contributor to the Pathogenesis of Psoriasis. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21176206"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1038\/jid.2013.182","article-title":"NF-\u03baB and STAT3 Inhibition as a Therapeutic Strategy in Psoriasis: In Vitro and In Vivo Effects of BTH","volume":"133","author":"Montesinos","year":"2013","journal-title":"J. Investig. Dermatol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the Pathogenesis of Psoriasis: From Keratinocyte Perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1038\/s41419-021-04284-5","article-title":"Inhibition of Keratinocyte Ferroptosis Suppresses Psoriatic Inflammation","volume":"12","author":"Shou","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"114745","DOI":"10.1016\/j.isci.2026.114745","article-title":"Factors Influencing the Proliferation of Keratinocytes in Psoriasis","volume":"29","author":"Liang","year":"2026","journal-title":"iScience"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Li, L., Liu, J., Lu, J., Wu, J., Zhang, X., Ma, T., Wu, X., Zhu, Q., Chen, Z., and Tai, Z. (2025). Interventions in Cytokine Signaling: Novel Horizons for Psoriasis Treatment. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1573905"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.15420\/ecr.2020.15.R2","article-title":"The Association Between Psoriasis and Cardiovascular Diseases","volume":"16","author":"Zwain","year":"2021","journal-title":"Eur. Cardiol."},{"key":"ref_109","doi-asserted-by":"crossref","unstructured":"Jiang, Z., Jiang, X., Chen, A., and He, W. (2023). Platelet Activation: A Promoter for Psoriasis and Its Comorbidity, Cardiovascular Disease. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1238647"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Tsoupras, A., Adamantidi, T., Finos, M.A., Philippopoulos, A., Detopoulou, P., Tsopoki, I., Kynatidou, M., Demopoulos, C.A., Tsoupras, A., and Adamantidi, T. (2024). Re-Assessing the Role of Platelet Activating Factor and Its Inflammatory Signaling and Inhibitors in Cancer and Anti-Cancer Strategies. Front. Biosci., 29.","DOI":"10.31083\/j.fbl2910345"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2174\/187152609788922555","article-title":"The Implication of Platelet Activating Factor in Cancer Growth and Metastasis: Potent Beneficial Role of PAF-Inhibitors and Antioxidants","volume":"9","author":"Tsoupras","year":"2009","journal-title":"Infect. Disord. Drug. Targets"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Salamah, M.F., Vallance, T.M., Kodji, X., Ravishankar, D., Williams, H.F., Brain, S.D., and Vaiyapuri, S. (2020). The Antimicrobial Cathelicidin CRAMP Augments Platelet Activation during Psoriasis in Mice. Biomolecules, 10.","DOI":"10.3390\/biom10091267"},{"key":"ref_113","first-page":"268","article-title":"Alantolactone-Loaded Chitosan\/Hyaluronic Acid Nanoparticles Suppress Psoriasis by Deactivating STAT3 Pathway and Restricting Immune Cell Recruitment","volume":"17","author":"Chen","year":"2022","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jid.2019.11.022","article-title":"Aryl Hydrocarbon Receptor in Cutaneous Vascular Endothelial Cells Restricts Psoriasis Development by Negatively Regulating Neutrophil Recruitment","volume":"140","author":"Zhu","year":"2020","journal-title":"J. Investig. Dermatol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jid.2022.09.004","article-title":"The P300\/CBP Inhibitor A485 Normalizes Psoriatic Fibroblast Gene Expression In Vitro and Reduces Psoriasis-Like Skin Inflammation In Vivo","volume":"143","author":"Kim","year":"2023","journal-title":"J. Investig. Dermatol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2022.09.028","article-title":"Malabaricone C Derived from Nutmeg Inhibits Arachidonate 5-Lipoxygenase Activity and Ameliorates Psoriasis-like Skin Inflammation in Mice","volume":"193","author":"Tsukayama","year":"2022","journal-title":"Free Radic. Biol. Med."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"4819","DOI":"10.1111\/jcmm.14392","article-title":"Transient Receptor Potential Ankyrin 1 (TRPA1) Positively Regulates Imiquimod-Induced, Psoriasiform Dermal Inflammation in Mice","volume":"23","author":"Zhou","year":"2019","journal-title":"J. Cell. Mol. Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Okada, F., Izutsu, R., Goto, K., and Osaki, M. (2021). Inflammation-Related Carcinogenesis: Lessons from Animal Models to Clinical Aspects. Cancers, 13.","DOI":"10.3390\/cancers13040921"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6780\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T11:39:44Z","timestamp":1785411584000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/15\/6780"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":118,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["ijms27156780"],"URL":"https:\/\/doi.org\/10.3390\/ijms27156780","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}